Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Virginia Mohlere

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
International Journal of Hematologic Oncology|March 6, 2023
Therapy-related core binding factor acute myeloid leukemiaBinsah George, Binoy Yohannan, Virginia Mohlere, et al.
The International Journal of Biological Markers|September 30, 2014
Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4Robert J Amato, Youxin Xiong, Hui Peng, et al.
Urologic Oncology|December 11, 2013
Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimusRobert J Amato, Amber Flaherty, Yufeng Zhang, et al.
Frontiers in Immunology|April 10, 2026
Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a reviewJames Fan Wu, Muhammad Abbas Abid, Sharda P Singh, et al.
Advances in Hematology|May 11, 2026
Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community SettingsAmrit S Gonugunta, Asad Haider, Virginia Mohlere, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 10, 2014
A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinomaRobert J Amato, Aditya Shetty, Yingjuan Lu, et al.
Cancer Medicine|May 19, 2019
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combinationPutao Cen, Curtis J Wray, Songlin Zhang, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
International Journal of Hematologic Oncology|March 6, 2023
Therapy-related core binding factor acute myeloid leukemiaBinsah George, Binoy Yohannan, Virginia Mohlere, et al.
The International Journal of Biological Markers|September 30, 2014
Clinical outcomes model in renal cell cancer patients treated with modified vaccinia Ankara plus tumor-associated antigen 5T4Robert J Amato, Youxin Xiong, Hui Peng, et al.
Urologic Oncology|December 11, 2013
Clinical prognostic factors associated with outcome in patients with renal cell cancer with prior tyrosine kinase inhibitors or immunotherapy treated with everolimusRobert J Amato, Amber Flaherty, Yufeng Zhang, et al.
Frontiers in Immunology|April 10, 2026
Evolving therapeutic pipeline for tumor-infiltrating lymphocytes in metastatic melanoma - a reviewJames Fan Wu, Muhammad Abbas Abid, Sharda P Singh, et al.
Advances in Hematology|May 11, 2026
Bispecific Antibodies in Hematologic Malignancies in the Outpatient and Community SettingsAmrit S Gonugunta, Asad Haider, Virginia Mohlere, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|April 10, 2014
A Phase I/Ib study of folate immune (EC90 vaccine administered with GPI-0100 adjuvant followed by EC17) with interferon-α and interleukin-2 in patients with renal cell carcinomaRobert J Amato, Aditya Shetty, Yingjuan Lu, et al.
Cancer Medicine|May 19, 2019
Durable response for ampullary and duodenal adenocarcinoma with a nab-paclitaxel plus gemcitabine ± cisplatin combinationPutao Cen, Curtis J Wray, Songlin Zhang, et al.
Pageof 1